Clin2
NCT06850480Possibly a fitRecruiting

Study of JP-1366 tablets for heartburn and acid reflux

Reflux Esophagitis (RE)

Part of Digestive system clinical trials.

This trial tests a new medication, JP-1366, for people with reflux esophagitis (damage to the esophagus from stomach acid). It aims to see if the drug is safe and effective at healing the esophagus and relieving symptoms like heartburn and regurgitation.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
356 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old.
  • You have had heartburn or regurgitation in the last 7 days, or a recent diagnosis of reflux esophagitis via endoscopy (a camera test of your esophagus).
  • You are willing to use effective birth control during the study (if applicable).
  • You do not have certain other gastrointestinal conditions, such as Barrett’s esophagus, active ulcers, or a history of surgery on your stomach or esophagus.
  • You have not used strong acid-reducing medications (like Nexium or omeprazole) in the last 2 weeks, or certain other acid blockers in the last week.
  • You do not have serious heart, liver, kidney, or bleeding problems that could increase risk.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07010107Recruiting· Phase 3
Testing anaprazole for moderate to severe reflux esophagitis

This trial tests a new medicine called anaprazole for people with moderate to severe reflux esophagitis (chronic heartburn and damage to the food pipe). It compares anaprazole to a standard treatment to see which works better and is safer.

Shanghai, Shanghai Municipality
NCT07160790Not yet recruiting· Phase 3
Study of JP-1366 for heartburn and acid reflux

This trial tests a new medicine, JP-1366, for people with non-erosive GERD (heartburn and acid reflux without visible damage to the esophagus). The goal is to see if it helps control symptoms better than a placebo.

NCT07732075Not yet recruiting· Phase 3
Study of JP-1366 for maintaining healing in erosive esophagitis

This trial tests a new medicine (JP-1366) to see if it can keep the esophagus healed in people who have been treated for erosive esophagitis. You may join if you are an adult with healed erosive esophagitis and have taken standard acid-blocking medication for at least 4 weeks.

NCT07624383Recruiting
New topical treatment for nonerosive acid reflux disease

This study tests a new topical treatment for people with chronic heartburn and acid regurgitation who don't have erosions (damage) in their esophagus. The treatment is applied directly to the affected area and may help relieve symptoms without taking daily pills.

Warsaw, Masovian Voivodeship
NCT04255693Recruiting
Real-life reflux study of diet and behavior changes

This study looks at how following specific diet and behavior changes affects symptoms of acid reflux (heartburn/regurgitation) in everyday life. It may help you understand what lifestyle steps improve reflux and how symptoms change over time.

Moscow
NCT06439563Recruiting· Phase 3
Testing JP-1366 to prevent NSAID-related stomach ulcers

This trial tests a new drug called JP-1366 to see if it can prevent stomach ulcers caused by long-term NSAID use (like ibuprofen or naproxen) for conditions such as arthritis. It may be a good fit if you need to take NSAIDs for at least 24 weeks and have a higher risk of ulcers.

Seoul

Hear when a new Reflux Esophagitis (RE) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.